The temporary pause follows reports of four cases of neurovascular events in the US external evaluation study.

Esophageal squamous cell carcinoma (ESCC) is a severe health threat, being a predominant subtype of esophageal cancer and ...

In that single-arm study, the rate of primary adverse events within 7 days of ablation was 2.9%, with the most common ...

The long-term safety of ibrutinib was proven in patients with newly diagnosed or relapsed or refractory (R/R) chronic ...

Pulsed field ablation (PFA) is emerging as an alternative, using non-thermal electric fields to target cardiac tissue while ...

Dofetilide is under clinical development by Hyloris Pharmaceuticals and currently in Phase I for Atrial Flutter.

About 200,000 Louisiana residents are living with a heart condition called atrial fibrillation but there is a new treatment ...

Looking back, Kokomo resident Mike Beatty knew he had something as a teenager, but he couldn’t put a name to it. Whenever he’d overexert himself, he’d feel “different,” but it would go away with rest.

The temporary halt to investigate reported neurovascular events comes two months after Johnson & Johnson won FDA approval for ...

The temporary pause will allow the company to investigate four neurovascular events seen in an external validation study.